Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels

References

• Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, . Tailored FEC compared with marrow-supported high-dose chemotherapy as adjuvant treatment of high-risk breast cancer patients: Results from a randomised study. Lancet 2000;356:1384–91.
   PubMed Web of Science ®Google Scholar
• Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, . Long-term follow-up of the SBG 9401 study comparing tailored FEC based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007; 18:694–700.
   PubMed Web of Science ®Google Scholar
• Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, . Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow supported high-dose chemotherapy with cyclophosphamide thiotepa, and carboplatin or tailored therapy with flourouracil, epirubicin, and cyclophophamide: Scandinavian Breast Group Study 9401. J Clin Oncol 2003;21:3659–64.
   PubMed Web of Science ®Google Scholar
• Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, . Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. Natl Cancer Inst 2002;94:1883–8.
   Google Scholar
• Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J, . Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581–8.
   PubMed Web of Science ®Google Scholar
• Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 2007;13:581–7.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, . The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measures. Acta Oncol 1991;30:947–57.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ C-36 in advanced melanoma: The CIPS questionnaire and proxy raters. Qual Life Res 1996;5:375–86.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, Grønvold M, Curran D, Bottomley A. EORTC QLQ-C30: Scoring Manual. Brussels, Belgium: European Organization for Research and Treatment of Cancer Quality of Life Study Group; 2002.
   Google Scholar
• Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89;1837–42.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Price K, Castiglione-Gertsch M, Coates A, Lindtner J, Collins J, . Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998;34:1693–700.
   PubMed Web of Science ®Google Scholar
• Paridaens R, Wildiers J, Dumez H. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): A retrospective analysis. Rowett L. Annals of Oncology. 27th ESMO Congress 2002, 18–22 October. Abstract 161. Nice: Oxford University Press; 2002. 45.
   Google Scholar
• Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763–6.
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Rissanden P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301–5.
   PubMed Web of Science ®Google Scholar
• Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246–57.
   PubMed Web of Science ®Google Scholar
• Szutowicz E, Radecka B, Dziadziuszko R. Peripheral blood count nadirs during adjuvant CMF chemotherapy for breast cancer – lack of prognostic relevance: 3rd European Beast Cancer Conference, Barcelona. Abstract 205. Eur J Cancer 2002;38(Suppl 3):S93.
   Google Scholar
• Bergh, J. Quo Vadis with targeted drugs. J Clin Oncol 2009; 27:2–5.
   PubMed Web of Science ®Google Scholar
• Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, . Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol 2007;25:5403–9.
   PubMedGoogle Scholar
• Luoma ML, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström P, . Physical performance, toxicity, and quality of life as assessed by the physician and the patient. Acta Oncol 2002;41:44–9.
   PubMed Web of Science ®Google Scholar
• Genre D, Protiére C, Macquart-Moulin G, Gravis G, Camerlo J, Alzieu C, . Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: Impact of length of cycles. Supp Care Cancer 2002;10:222–30.
   PubMedGoogle Scholar
• Hurria A, Somio G, Ahles T. Renaming “Chemobrain”. Cancer Invest 2007;25:373–7.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 2003;95:190–7.
   PubMed Web of Science ®Google Scholar
• Fayers P, Bottomley A. Quality of life research within the EORTC – the EORTC QLQC30. Eur J Cancer 2002;38: S125–33.
   PubMedGoogle Scholar